



4555 Mansell Road, Suite 300, Alpharetta,
GA 30022
Tel: +1 (844) 884 5367
Email: info@vtivision.com
www.vtvision.com
www.vtvisioninvestors.com (for investors)

ASX Announcement

Visioneering Technologies, Inc. strengthens Board of Directors with new appointment

Atlanta, Georgia, USA 3 May 2017: Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lenses is pleased to announce the appointment of Mr Tom Dooley to Visioneering's Board of Directors as a Non-Executive Director.

Mr Dooley most recently served as President of Alcon Japan LTD, where he was responsible for 1,300 employees and over US\$1B in annual sales of Alcon Laboratories' products, including medical devices, pharmaceuticals, and contact lens care products. Prior to moving to Japan, he served as Alcon's Country Manager in Australia and New Zealand. His appointment brings deep executive-level experience and knowledge to the VTI board, acquired through his 27 years of senior business leadership roles in healthcare and ophthalmology.

Dr Stephen Snowdy, CEO and Executive Director at Visioneering Technologies, said: "On behalf of Visioneering's executive leadership and Board of Directors, we warmly welcome Mr Dooley to the Company. Mr Dooley will contribute to VTI's management a lifetime of experience and strategic guidance during our rapid sales force expansion, growth of the organization, and expansion into international markets. We are excited to add another independent board member who understands our industry well, and we look forward to working with him on new endeavours."

Mr Dooley holds a Bachelor of Science in Agricultural Economics from Purdue University.

For more information, please contact:

Company	Investor and media relations
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: ssnowdy@vtivision.com	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal (MF) contact lens. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

The NaturalVue MF contact lens employs VTI's Neurofocus Optics™ technology, which was developed, refined and tested over many years. NaturalVue lenses were cleared by the FDA in late 2014 for the correction of refractive errors and VTI commenced a pilot US market launch of NaturalVue MF contact lenses from 2015 that gave way to a broader US launch in 2016 and 2017. VTI sells and plans additional contact lens products.

Foreign ownership restrictions:

VTI's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

MKT-VTI-PR24 r0